Tag: Blueprint Medicines

CHMP adopts positive opinion for avapritinib for PDGFRA D842V mutant GIST

pharmanewsdaily- July 26, 2020

US precision therapy company Blueprint Medicines said that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a ... Read More

Blueprint Medicines strikes $1.7bn worth deal with Roche for pralsetinib

pharmanewsdaily- July 15, 2020

Swiss pharma giant Roche and US precision therapy company Blueprint Medicines have entered into a worldwide licensing and collaboration deal potentially worth up to $1.703 ... Read More

FDA rejects Blueprint’s NDA for AYVAKIT for treatment of fourth-line GIST

pharmanewsdaily- May 15, 2020

Blueprint Medicines said that the US Food and Drug Administration (FDA) has rejected its new drug application (NDA) for AYVAKIT (avapritinib) for the treatment of ... Read More